Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Transarterial Chemoembolization in Combination With Tislelizumab and Lenvatinib for Advanced Stage HCC (CHANCE2602)

NCT07836309 is registered in ClinicalTrials.gov with Zhongda Hospital as lead sponsor.

NCT NCT07836309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07836309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Transarterial Chemoembolization in Combination With Tislelizumab and Lenvatinib for Advanced Stage HCC (CHANCE2602)
Lead sponsor
Zhongda Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 31, 2027
Enrollment
596 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)